ChemoCentryx

OverviewSuggest Edit

ChemoCentryx is a biopharmaceutical company developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of our drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. The Company's drug candidates are small molecules, which are orally administered, offering significant quality of life benefits, since patients swallow a capsule or pill instead of having to visit a clinic for an infusion or undergo an injection.

... Show more
TypePublic
Founded1997
HQMountain View, USMap
Websitechemocentryx.com
Employee Ratings2.3More
View Jobs (4)

Recent NewsAll News

Latest Updates

Employees (est.) (Feb 2019)66
Job Openings4
Revenue (FY, 2017)$82.5 M(+592%)
Share Price (Feb 2019)$11 (+3%)

Key People/Management at ChemoCentryx

Thomas J. Schall

Thomas J. Schall

President, Chief Executive Officer and Chairman of the Board
Markus J. Cappel

Markus J. Cappel

Chief Business Officer and Treasurer
Show more

ChemoCentryx Office Locations

ChemoCentryx has an office in Mountain View
Mountain View, US (HQ)
850 Maude Avenue
Show all (1)
Report incorrect company information

ChemoCentryx Financials and Metrics

ChemoCentryx Revenue

ChemoCentryx's revenue was reported to be $82.50 m in FY, 2017
USD

Net income (Q3, 2018)

(10.9m)

EBIT (Q3, 2018)

(11.5m)

Market capitalization (15-Feb-2019)

572.0m

Closing stock price (15-Feb-2019)

11.0

Cash (30-Sep-2018)

24.1m

EV

562.6m
ChemoCentryx's current market capitalization is $572 m.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

Revenue

11.9m82.5m

General and administrative expense

11.6m14.5m14.7m16.5m

R&D expense

33.5m33.2m37.9m49.5m

Operating expense total

45.2m47.7m52.7m66.0m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

2.8m4.3m8.2m8.9m9.0m9.5m

General and administrative expense

2.9m3.5m3.4m3.5m3.7m3.6m3.8m4.1m3.9m3.2m4.6m4.2m3.6m4.7m4.7m5.4m

R&D expense

8.2m8.1m9.0m7.5m8.4m8.6m7.9m11.2m9.1m8.4m10.0m14.3m12.3m14.7m17.8m15.1m

Operating expense total

11.1m11.7m12.4m11.1m12.1m12.2m11.7m15.3m12.9m11.6m14.5m18.5m15.9m19.4m22.5m20.5m
show all
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

10.3m16.1m12.8m12.0m40.0m

Accounts Receivable

30.2m51.1m

Inventories

596.0k972.0k757.0k722.0k

Current Assets

134.3m74.3m72.0m148.7m179.8m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

22.3m11.6m13.1m20.9m25.4m11.6m14.6m13.4m21.9m13.9m19.0m21.5m18.0m30.6m68.8m24.1m

Accounts Receivable

175.0k120.0k30.2m218.0k530.0k1.7m164.0k336.0k

Inventories

1.3m

Current Assets

125.6m133.7m100.8m86.1m76.1m71.4m74.2m65.2m127.0m122.7m119.9m124.2m122.4m149.8m184.9m176.1m
show all
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(38.7m)(46.9m)(47.3m)(40.0m)17.9m

Depreciation and Amortization

576.0k543.0k477.0k348.0k418.0k

Inventories

Accounts Payable

159.0k(161.0k)(73.0k)(4.0k)729.0k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(29.1m)(11.5m)(12.3m)(34.7m)(12.0m)(24.1m)(11.6m)(15.2m)(25.2m)(32.3m)(6.0m)(15.2m)(21.8m)(9.4m)(16.3m)(27.2m)

Depreciation and Amortization

426.0k153.0k414.0k259.0k86.0k173.0k260.0k203.0k311.0k111.0k227.0k371.0k

Inventories

1.3m

Accounts Payable

(58.0k)(199.0k)690.0k121.0k809.0k280.0k615.0k619.0k(162.0k)165.0k819.0k704.0k682.0k(951.0k)(378.0k)(824.0k)
show all
USDY, 2018

EV/EBIT

-48.8 x

EV/CFO

17.7 x

Debt/Equity

0.7 x

Debt/Assets

0.1 x

Financial Leverage

8.9 x
Show all financial metrics
Report incorrect company information

Competitors

Biogen
Healthcare - Public
MyoKardia
Healthcare - Public
Athersys
Healthcare - Public
Reata Pharmaceuticals
Healthcare - Public
Compare competitors

ChemoCentryx News and Updates

January 24, 2019

ChemoCentryx Announces Withdrawal of Phase II-Based Conditional Marketing Authorization (CMA) Application for ANCA-Associated Vasculitis in Europe; Phase III ADVOCATE Trial Data Release Planned for Q4 2019

-- Companies plan to file for full marketing approval to EMA and FDA in 2020 -- -- Companies plan to file for full marketing approval to EMA and FDA in 2020 --
September 26, 2018

ChemoCentryx Announces Proposed Public Offering of Common Stock

MOUNTAIN VIEW, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has commenced an underwritten public offering of $75 million of its common stock.  In connection with this offering, ChemoCentryx plans to grant the underwriters a 30-day option to pu…
May 09, 2018

ChemoCentryx's (CCXI) CEO Dr. Thomas Schall on Q1 2018 Results - Earnings Call Transcript

May 07, 2018

ChemoCentryx: Discounted, Underfollowed, And Misunderstood Biotech

March 23, 2018

ChemoCentryx: Significant Progress In Recent Months

Report incorrect company information

ChemoCentryx Blogs

January 02, 2019

ChemoCentryx to Present at the 37th Annual J.P. Morgan Healthcare Conference

ChemoCentryx to Present at the 37th Annual J.P. Morgan Healthcare Conference Content Import Wed, 01/02/2019 - 08:36 ChemoCentryx to Present at the 37th Annual J.P. Morgan Healthcare Conference 01/02/19 This release is a backfill from a News Wire …
November 29, 2018

ChemoCentryx’s Novel Small Molecule Antagonists of Checkpoint Inhibitors and Chemokine Receptors to be Presented at the American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Conference

-- Studies highlight CCX4503, a unique small molecule inhibitor of immune checkpoint molecules PD-1/PD-L1, demonstrates anti-tumor efficacy in vivo -- -- Company’s studies also show CCR4 inhibition enhances effectiveness of checkpoint inhibition in tumor models in vivo -- MOUNTAIN VIEW, Calif.
November 20, 2018

ChemoCentryx to Present at the 30th Annual Piper Jaffray Healthcare Conference

MOUNTAIN VIEW, Calif. , Nov. 20, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday November 27, 2018 at 8:30 a.m. ET .
September 28, 2018

ChemoCentryx Determines Not to Proceed with Public Offering of Common Stock

MOUNTAIN VIEW, Calif. , Sept. 27, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (the "Company" or "ChemoCentryx") (Nasdaq:CCXI) announced today that it will not conclude an offering of shares of its common stock as announced on Wednesday, September 26, 2018 .
September 26, 2018

ChemoCentryx to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

MOUNTAIN VIEW, Calif. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Tuesday October 2, 2018 at 1:40 p.m. ET .

ChemoCentryx Company Life and Culture

Report incorrect company information

 ChemoCentryx Frequently Asked Questions

  • When was ChemoCentryx founded?

    ChemoCentryx was founded in 1997.

  • Who are ChemoCentryx key executives?

    ChemoCentryx's key executives are Thomas J. Schall and Markus J. Cappel.

  • How many employees does ChemoCentryx have?

    ChemoCentryx has 66 employees.

  • What is ChemoCentryx revenue?

    Latest ChemoCentryx annual revenue is $82.5 m.

  • What is ChemoCentryx revenue per employee?

    Latest ChemoCentryx revenue per employee is $1.2 m.

  • Who are ChemoCentryx competitors?

    Competitors of ChemoCentryx include Biogen, MyoKardia and Athersys.

  • Where is ChemoCentryx headquarters?

    ChemoCentryx headquarters is located at 850 Maude Avenue, Mountain View.

  • Where are ChemoCentryx offices?

    ChemoCentryx has an office in Mountain View.

  • How many offices does ChemoCentryx have?

    ChemoCentryx has 1 office.